The FDA approved GO in 2017 and the EMA approved it in 2018 as monotherapy or combined with standard cytarabine/daunorubicin chemotherapy for the treatment of adults (ages ≥15 years in Europe) with newly diagnosed, CD33‐positive AML. Here, CD33 is linked to acute myeloid leukemia.